|Articles|September 1, 2000

Implementing Optimal Guidelines for Growth Hormone Use in a Managed Care Population
Volume 6
Issue 15 Suppl

Clinical and Reimbursement Issues on Growth Hormone Use in Adults

Author(s)Benerly M.K. Biller, MD, Mary Lee Vance, ND, David L. Kleinberg, MD

Download PDF: Clinical and Reimbursement Issues on Growth Hormone Use in Adults

Articles in this issue

about 26 years ago

Article

Participating Faculty

about 26 years ago

Article

Introduction

about 26 years ago

Article

Growth Hormone Use in Pediatric Growth Hormone Deficiency and Other Pediatric Growth Disorders

about 26 years ago

Article

Growth Hormone Use in Transitioning Patients -- Clinician and Payer Concerns

about 26 years ago

Article

Recommendations on Improving the Use of and Managed Care Review Process of Growth Hormone Therapy

about 26 years ago

Article

Clinician and Payer Issues in Managing Growth Hormone Deficiency

about 26 years ago

Article

CME / CPE / CCMCE Quiz

about 26 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Clinical and Reimbursement Issues on Growth Hormone Use in Adults

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 August FDA Approvals Marked by Novelty, Pushback

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation